TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based on treatment-emergent adverse events of chemotherapy (modFOLFIRINOX) or device (TTFields). The main questions it aims to answer are: * Is TTFields treatment safe for the patients in combination with modFOLFIRINOX? * Are participants compliant with the treatment? * Is Is TTFields treatment effective in combination with modFOLFIRINOX against metastatic pancreatic adenocarcinoma?
Eligibility Criteria
Inclusion Criteria: All the patients should comply with the following criteria for inclusion: 1. Histological/cytological diagnosis of pancreatic adenocarcinoma. 2. The patient should be 18 years of age and older. 3. The patient has given consent to participate in the study. 4. The patient should be able to comply with all the requirements of the clinical trial. 5. Life expectancy of at least 3 months. 6. Metastatic disease with, at least, one hepatic lesion that must be accessible for biopsy. 7. Measurable disease as defined by Response Evaluation Criteria in Solid Tumor v1.1 (RECIST 1.1) apart from the liver lesion to be biopsied. 8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 9. Amenable and assigned by the investigator to receive therapy with modFOLFIRINOX. 10. Prior chemotherapy or radiotherapy on the neoadjuvant or adjuvant setting is allowed as long as at least six months have elapsed since last chemotherapy treatment. 11. Able to operate the Novo TTF